City Therapeutics priced a $200 million IPO to fund an RNAi pipeline framed as “Alnylam 2.0,” highlighting tissue delivery beyond the liver as an ongoing focus. The offering supports medicines in or near clinical testing alongside earlier RNAi research aimed at improving extrahepatic access. The listing reinforces that RNAi developers are still pursuing scale-through-public-markets economics while competing for capital efficiency and delivery differentiation. Market reception will likely hinge on near-term clinical catalysts and pharmacology proof points that demonstrate meaningful target engagement outside the liver.